anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a plaster having balanced transcutaneous absorbability of drug and skin irritation and suitable for repeated application to the same part of the skin by using a plaster layer composed of a specific composition and a tacky adhesive material consisting of a polymeric substance having carboxyl group. CONSTITUTION:The objective plaster can be prepared by compounding (A) a fatty acid glycerol ester (e.g. glycerol monooleate) and (B) an alkali metal hydroxide to (C) a tacky adhesive agent consisting of a polymeric substance having carboxyl group, preferably and acrylic polymer containing >= 50 wt.% of (meth)acrylic acid ester having alkyl groups having an average C number of >= 4 and copolymerized with a copolymerizable functional monomer and laminating the obtained plaster layer to a flexible substrate. Preferably, the thickness of the plaster layer is 10-100mum and that of the substrate is 5-150mum. When a drug is compounded to the plaster, the drug can be stably held in the plaster to prevent the decrease of the drug content. Excellent effect can be attained especially in the case of using a drug having carboxyl group.
The quick release preparation for targeted therapy of heart failure consists of a base solution and drug-loaded microvesicles. The components of the basic solution comprise poloxamer and hydroxyethyl starch, and the mass ratio of the poloxamer to the hydroxyethyl starch is 1: 10. The drug-loaded microvesicles consist of nitric oxide microvesicles carrying basic fibroblast factors. The nitric oxide microvesicle is formed by wrapping nitrogen monoxide by a vesicle membrane material of hydrogenated soybean phospholipid and heparin-poloxamer, and the mass ratio of the hydrogenated soybean phospholipid to the heparin-poloxamer is 1: 2. The molar mass of the basic fibroblast factor is equal to that of the heparin-poloxamer, and the basic fibroblast factor is adhered to the surface of the nitric oxide microbubble. The particle size range of the medicine-carrying microvesicle is 2-5 μm, and the concentration is 6 multiplied by 10 6 ～9×10 6 one/mL. The quick release preparation for targeted therapy of heart failure realizes accurate positioning and targeted delivery of heart parts by an ultrasonic mediated technology after intravenous injection, and is used for the therapy of heart failure.
Participants received placebo matched to Dupilumab and placebo matched to Timothy grass subcutaneous immunotherapy (SCIT) every 2 weeks (Q2W) for 16 weeks. Both placebo doses were administered with a gap of 1 or 7 days.
PURPOSE: Brazil has one of the world's highest numbers of patients on hemodialysis (HD). Most dialysis centers are private and perform HD for patients with private and public health insurance. We compared 1-year survival between patients initiating chronic HD with public and private health insurance.
METHODS: This is an HD register-based retrospective cohort. Adult patients starting HD from January 2011 to December 2021 were included. Survival analysis was stratified according to the period entered in the HD register. Multivariate Cox regression focused on 1-year survival differences between private and public patients.
RESULTS: In the final sample (n = 5114), 68.5% of participants had public and 31.3% to private health insurance, with overall 1-year survival of 92.8% and 89.9%, respectively (p = 0.002). Crude analysis showed a slightly higher survival rate among patients with public health insurance than those with private health insurance (91 vs. 87%, p = 0.030) in the first period (2019-21). However, the adjusted hazard ratio (HR) did not remain significantly higher for patients with private health insurance compared to those with public health insurance (HR = 1.07; 95% CI 0.80-1.41; p = 0.651), even after propensity score matching of the groups by several baseline features.
CONCLUSION: Brazilian chronic HD patients funded by either private health plans or the public system have a similar 1-year mortality risk after controlling for several sociodemographic and clinical parameters.
Patients who are treated with the combination therapy of Azvudine and Chinese herbal medicine will be included in this group. The combination therapy is Azvudine treatment (5 mg once a day) within 48 hours of first positive nucleic acid testing for COVID-19, combined with Chinese herbal medicine treatment.
Pinewood, increasingly used in construction and interior fittings, emits high amounts of volatile organic compounds (VOCs), which tend to accumulate in indoor air. Whether indoor VOCs affect the development of atopic dermatitis (AD) is a matter of debate. We aimed to evaluate the effects of pinewood VOCs on the development of AD-like inflammatory phenotype and linked microbiome alterations, both hallmarks of AD. An oxazolone-induced mouse model of AD was exposed to three different VOC concentrations emitted by pinewood plates throughout the experiment. The disease course and associated immunological and microbiological changes were evaluated. To validate and translate our results to humans, human keratinocytes were exposed to a synthetic pinewood VOCs mixture in an AD environment. Pinewood emitted mainly terpenes, which at a total concentration of 5 mg/m3 significantly improved oxazolone-induced key AD parameters, such as serum total IgE, transepidermal water loss, barrier gene alteration, inflammation, and dysbiosis. Notably, exposure to pinewood VOCs restored the loss of microbial richness and inhibit Staphylococci expansion characteristic of the oxazolone-induced mouse AD model. Most beneficial effects of pinewood VOCs were dose-dependent. In fact, lower (<3 mg/m3) or higher (>10 mg/m3) pinewood VOC levels maintained only limited beneficial effects, such as preserving the microbiome richness or impeding Staphylococci expansion, respectively. In the human in-vitro model, exposure of keratinocytes grown in an AD environment to a pinewood VOCs mixture reduced the release of inflammatory markers. In conclusion, our results indicate that airborne phytochemicals emitted from pinewood have beneficial effects on an AD-like phenotype and associated dysbiosis. These investigations highlight the effects of terpenes as environmental compounds in the prevention and/or control of atopic skin disease.
Untrained males aged 22±1.5 years were randomly assigned to exercise training (ET) with or without post-exercise sauna treatments (S). Participants in the group ET+S (n=8) exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment. The control group (ET, n=7) engaged in the same exercise training program without the sauna treatments. Blood and stool samples were collected before and after the 4-week training program. Blood samples were analysed for the concentration of high-sensitivity C-reactive protein (hsCRP) and complete blood counts. Stool samples were analysed for pH, quantitative and qualitative measures of targeted bacteria and fungi, zonulin, and secretory immunoglobulin A. This study evaluated the effects of post-exercise sauna bathing in young men undergoing endurance training on gut bacteria inflammation and intestinal barrier function. Investigators hypothesized that sauna bathing applied immediately after a physical training session may impact homeostatic control of the gut microbiota and the function of the intestinal barrier.
PROBLEM TO BE SOLVED: To obtain a shampoo composition effective for exterminating a lice by adding a specific compound as an active ingredient to the shampoo composition containing an anionic surfactant and also blending a polyhydric alcohol in a specific ratio. SOLUTION: This shampoo composition is obtained by containing 0.001-5wt.% pyriproxyfen: [4-phenoxyphenyl-2-(2-pyridyloxy)propylether], 10-70wt.% anionic surfactant and 0.5-20wt.% polyhydric alcohol. As the anionic surfactant, one or more kinds selected from a sulfuric ester salt, a sulfonic acid salt and a carboxylic acid salt, is preferable. As the polyhydric alcohol, ethylene glycol, propylene glycol and their (co)polymers are preferable. Also, another insecticide, especially a pyrethroid compound (phenothrin, permethrin, allethrin, etc.) is allowed to be added by approximately 1-8wt.%.
BACKGROUND: Despite the significant impact of blindness on the affected individuals' quality of life, its burden has not been assessed according to temporal cause-specific changes in severity, impeding our ability to evaluate the impact of blindness on population health accurately. Therefore, we aimed to comprehensively quantify the changes in cause-specific blindness burden according to changes in disease severity for 18 causes of blindness.
METHODS: For this cross-sectional population-based study, we derived data on prevalence, disability-adjusted life-years (DALYs), and population size between 1990 and 2019 from the Global Burden of Disease 2019 study. Using the decomposition method, we attributed changes in total DALYs to population growth, population ageing, and changes in prevalence rate and disease severity between 1990 and each subsequent year globally, regionally, nationally, and by sex, cause, and sociodemographic index (SDI). The absolute and relative contributions to the variation in blindness-related DALYs between 1990 and each year from 1991 to 2019 then served as a measure of changes in disease severity.
RESULTS: Changes in disease severity from 1990 to 2019 were associated with 15 165.11 DALYs in men and 20 639.32 DALYs in women. We observed disease severity increases in most countries/territories, with attributable DALY proportions ranging from -0.07% to 1.30% in men and from -0.06% to 1.73% in women. Notably, both attributable proportions and DALYs were greater in women than men. The largest increases in attributable DALYs were observed for cataracts, refraction disorders, and glaucoma globally; age-related macular degeneration in high-SDI countries; and trachoma and retinopathy of prematurity in lower-SDI countries.
CONCLUSIONS: Growth in the burden of cause-specific blindness due to increased disease severity reflects the lag of healthy vision life behind increasing life expectancy, necessitating the implementation of preventive and long-term therapeutic measures focussed on improving visual outcomes.
ADHD affects from 3 to 5% of children, persists into adolescence in 40 to 70% of these children and continues into adulthood in at least 50% of affected adolescents. Methylphenidate was the first medication shown to be effective in treatment for adults with ADHD and continues to be widely used. While the extended release formulations represent an improvement over the immediate release versions, significant problems remain for many patients. In particular, most have been designed with the goal of providing medication only during school hours and a short time period after school. In adults, there is a frequent need for much more extended duration of treatment. MTS is a new form of methylphenidate that provides medication in a transdermal patch delivery system. It has a very even, slowly ascending pharmacokinetic profile. MTS's very stable slowly increasing blood level should overcome the problems noted above with a delivery system that is more convenient for many patients. It is currently approved for treatment of childhood ADHD, with effectiveness and safety profiles similar to other forms of methylphenidate. This study will be the first to evaluate the effectiveness and safety of MTS in adult ADHD.

This is a double-blind, placebo-controlled, randomized, crossover trial comparing MTS with placebo patch. The double-blind trial will be preceded by an enrollment period consisting of two screening visits followed as quickly as possible by a baseline visit. Patients who continue to meet admission criteria at baseline will be randomized into the first of two 4-week treatment periods. We will attempt to reach the highest tolerated dose size of MTS within 2 weeks and then observe the response over the last two weeks of each crossover phase. The double-blind period will be followed by a 180 day open-treatment, flexible-dose phase designed to assess long-term effects.
On Study Day 1 in both sites, women selecting RFU will receive 3 laboratory requisition forms for serum β-hCG testing and will be instructed to have testing done at a laboratory site of her choice on Study Day 10-12. The follow-up telephone appointment will be scheduled to take place on Study Day 15 (±3 days). For the follow-up telephone appointment, the research nurse/nurse practitioner will calculate the percentage fall in the β-hCG value. She will contact the subject by phone at the specified time, take a history of the timing of misoprostol use, resulting symptoms and complete the symptom Post-abortion Check-list. The research nurse/nurse practitioner, in consultation with the clinic physician if necessary, will confirm the information, determine whether other follow-up is required.
Study design This is a multi-center prospective observational study performed over a 12-month period (from August 2022 to August 2023). The research premise was granted approval by the local Ethics Committee (2020ZDSYLL303-P02).

VOX index The VOX index was defined as the ratio of SpO2/FiO2 over VT. Investigators briefly interrupted HFNC (3 minutes) to measure VT using a mechanical ventilator (SV800, Mindray) in noninvasive ventilation (NIV) mode, as an "NIV test". Inspiratory support was set at 5 cmH2O and 5 cmH2O positive end-expiratory pressure level for all patients, and initial oxygen concentration was set as in HFNC. NIV was delivered through a face mask (ZS-MZ-A, Zhongshan Medical) and a double-pipe system, while minimizing leaks. In consideration of variations in VT, we recorded mean VT and respiratory rate for 1 minute under stable conditions.

Study protocol HFNC therapy was started within 15 minutes after recruitment and initiated with a 30-40 LPM minimum flow. Investigators adjusted FiO2 as suitable, targeting SpO2 of 92% or more, and the rate of flow set on the basis of the physician's decision. HFNC discontinuation and invasive mechanical ventilation (IMV) initiation were based on the intubation criteria defined in investigators clinical protocol, finial decisions were made by the physicians in charge, who were blinded to the VT during NIV test. HFNC failure was defined as a need for IMV, on account of NIV is not employed as the second line of ventila,ory support in the event of HFNC failure, in the participating units. Patient demographics, comorbidities, and chest radiographs prior to HFNC initiation were documented upon inclusion into the research analysis. The acute physiologic assessment and chronic health evaluation II (APACHE II) score along with the sequential organ failure assessment score (SOFA) were documented based on the highest scores in the 24h previous HFNC initiation. The time of HFNC onset was defined as 0h. Vital signs; HFNC settings including FiO2, flow rate, and temperature; clinical respiratory variables including RR, VT, and SpO2; diaphragmatic ultrasonography including diaphragmatic displacement, diaphragm thickness (tdi), and Δtdi% (was calculated as \[tdi end-inspiration-tdi end-expiration/tdi end-expiration\] ×100) were recorded at 0, 2, 6, 12, 18, and each 24h pre day following initiation of HFNC treatment until day 7. Variables of pulmonary gas exchange variables with the arterial line were documented at 0, 6, 12 and each 24h pre day following initiation of HFNC treatment until day 7 after initiation of HFNC treatment.
PURPOSE: A method for preparing Cr-chelating agent is provided to reduce production cost and to enhance feed use efficiency. CONSTITUTION: A metal chelating agent contains defatted soybean meal hydrolysate as an active ingredient. The hydrolysate is prepared by hydrolyzing defatted soybean meal powder using protease. The hydrolysis is performed at pH 7.5-9.0 and 45-55 °C. A Cr-chelate compound contains the metal chelating agent and chromium. A method for preparing the Cr-chelate compound comprises coordinate covalent bond of the chromium(III) chloride as reactant and the hydrolyste as a metal chelating agent. A feed additive composition contains the Cr-chelate compound as an active ingredient.
The kit useful e.g. in slimming and smoothening the body, comprises a container (2) having a product to be applied on the human body e.g. neck, belly and thighs, an impermeable extensible band (3) closed/reclosed on itself around a region of the body to be treated and a closing system (30). The band has an internal face (6) defined by a porous material layer absorbing the product. The closing system comprises a fixing unit with co-operation forms such as magnetic or adhesive hooks, loops, snap fastener and zipper. The kit useful e.g. in slimming and smoothening the body, comprises a container (2) having a product to be applied on the human body e.g. neck, belly and thighs, an impermeable extensible band (3) closed/reclosed on itself around a region of the body to be treated and a closing system (30). The band has an internal face (6) defined by a porous material layer absorbing the product. The closing system comprises a fixing unit with co-operation forms such as magnetic or adhesive hooks, loops, snap fastener and zipper. The closing system comprises a maintenance element on the band such as a grip, a safety pin or a tie, and is carried by the band. The container comprises a system for measured distribution of the product in the form of liquid, cream, gel, pulverulent or stick. The band comprises an absorbent interior layer of absorbent material defining partially the interior face by a fibrous interior layer such as textile, knitting layer, non-woven layer and flocking layer. The product contains volatile solvent. The band comprises internal layer of honeycomb cellular foam structure, and a layer-forming barrier of impermeable material to the product. The layer-forming barrier is permeable to the water vapor or vapor of the product, distant from the non-null distance of the interior face and is separated by the absorbent interior layer. The layer-forming barrier defines partially the external face of the band. The external layer defines a non-smooth external surface. Package (4) comprises the band and the container. The closing system regulates the perimeter of the band on an area of 5 cm. The band has a constant width of 3-60 cm and an elongation capacity (10%). The kit has size tags for the adjustment of the perimeter of the band. An independent claim is included for a cosmetic treatment.
FIELD: food-processing industry. SUBSTANCE: biologically active food additive contains oil seeds, such as grape seeds, ground in two stages. At first stage, grape seeds are ground, at second stage ground seeds are subjected to fine grinding in fat medium in 0.1-2.0 mm thick film at temperature of 50-60 C and fat flow rate of 0.3-0.5 m/s. Additive contains at least 7.0 mg % of vitamin PP and at least 1,500 mg % of mineral substance. Biologically active additive is used for obtaining of food products with increased biological and physiological value and produces marked curing and therapeutic effect. EFFECT: improved quality of food product. 3 cl, 4 ex
BACKGROUND: Doxorubicin and other anthracyclines are crucial cancer treatment drugs. However, they are associated with significant cardiotoxicity, severely affecting patient care and limiting dosage and usage. Previous studies have shown that low carbon monoxide (CO) concentrations protect against doxorubicin toxicity. However, traditional methods of CO delivery pose complex challenges for daily administration, such as dosing and toxicity. To address these challenges, we developed a novel oral liquid drug product containing CO (HBI-002) that can be easily self-administered by patients with cancer undergoing doxorubicin treatment, resulting in CO being delivered through the upper gastrointestinal tract.
METHODS AND RESULTS: HBI-002 was tested in a murine model of doxorubicin cardiotoxicity in the presence and absence of lung or breast cancer. The mice received HBI-002 twice daily before doxorubicin administration and experienced increased carboxyhemoglobin levels from a baseline of ≈1% to 7%. Heart tissue from mice treated with HBI-002 had a 6.3-fold increase in CO concentrations and higher expression of the cytoprotective enzyme heme oxygenase-1 compared with placebo control. In both acute and chronic doxorubicin toxicity scenarios, HBI-002 protected the heart from cardiotoxic effects, including limiting tissue damage and cardiac dysfunction and improving survival. In addition, HBI-002 did not compromise the efficacy of doxorubicin in reducing tumor volume, but rather enhanced the sensitivity of breast 4T1 cancer cells to doxorubicin while simultaneously protecting cardiac function.
CONCLUSIONS: These findings strongly support using HBI-002 as a cardioprotective agent that maintains the therapeutic benefits of doxorubicin cancer treatment while mitigating cardiac damage.
The invention is concerned with a kind of traditional Chinese and western medicine and ite preparation method and quality control method to cure athlete's foot, ringworm of the hand and tinea unguium. It relates to 10 to 500 mL compound coral ginger tincture, 1 to 50 g oxybenzoic acid, 1 to 50 g glycerin and 1 to 50 g acetic acid, and with some assistant materials. The preparation of this invention uses traditional Chinese and western medicine to adjust the balance of qi and blood of crus cerebri and kill fungus. The tincture has strong osmosis to solve horn of skin with better cure effect. The nebula added with film forming agent can reduce the volatilization of madicine and keep work for long time. The prepared liniment is easy for use and has perfect effect. This quality control method cotrols the quality of medicine and keeps the cure effect and safety.
The invention aims at providing a traditional Chinese medicine used for treating gastric disease, and a preparation method thereof. The medicine is prepared from the medicine materials of, by weight: 10-14 parts of pearl powder, 9-30 parts of Niujie herb, 12-50 parts of common bletilla tuber, 12-50 parts of corydalis tuber, 12-50 parts of nacre, 10-40 parts of rhubarb, 15-60 parts of chicken's gizzard-membrane, and 9-30 parts of balloonflower root. According to principles of monarch, minister, assistant, and guide drugs in traditional Chinese medical science, liver soothing, spleen strengthening, gastro-intestine regulating, and body immunity enhancing are performed when gastric diseases are treated. Therefore, both the symptoms and the underlying causes are treated, and a comprehensive treatment effect of rehabilitation and health-care is achieved. The cost is low, and the effect is substantial. The medicine is mainly used for treating various gastric diseases such as gastritis, stomach ulcer, gastric hemorrhage, gastric perforation, various gastric mucosa diseases, antral gastritis, and duodenal ulcer. The medicine has a high curative effect against gastric diseases except gastric cancer, and has a substantial treatment effect against intestinal diseases. Therefore, the purpose of the invention is achieved.
Provided herein are, inter alia, compositions and methods for improved production of SC-? cells in vitro. For example, provided are novel formulations and differentiation methods that result in higher cell yields and recoveries, increased numbers and relative percentages of SC-? cells, enhanced stability and shelf-life of SC-? cells, SC-islet clusters with advantageous characteristics such as reduced size and increased uniformity, improved function of the SC-? cells in vitro, and improved viability, function, and reduced immunogenicity after transplantation. The disclosed compositions and methods can be employed in the manufacture of SC-islets for human therapeutic use.